...
机译:延迟抗逆转录病毒治疗的HIV 1型感染可检测抗药性病毒血症患者的治疗转换不会对免疫参数产生深远影响:AIDS临床试验小组研究A5115
Department of Medicine, Rush Medical College, Chicago, Illinois 60612.;
Department of Biostatistics, Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts 02319.;
Department of Biostatistics, Statistical and Data Analysis Center, Harvard School of Public Health, Boston, Massachusetts 02319.;
Social & Scientific Systems, Inc., Silver Spring, Maryland 20910.;
Section of Retroviral Therapeutics, Brigham and Women's Hospital and Division of AIDS, Harvard Medical School, Boston, Massachusetts 02319.;
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27706.;
Department of Medicine, University of California–San Francisco and San Francisco General Hospital, San Francisco, California 94143.;
Department Immunology and Microbiology, Rush Medical College, Chicago, Illinois 60612.;
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15260.;
机译:在具有可检测到的耐药病毒血症的抗逆转录病毒治疗的HIV 1型感染患者中延迟治疗切换不会对免疫参数产生深远影响:AIDS Clinical Trials Group Study A5115。
机译:在具有抗药性人类免疫缺陷病毒1型的抗逆转录病毒药物治疗的个体中,强大的细胞介导的免疫反应与维持低水平病毒血症有关。
机译:计划在HIV 1型感染的儿科人群中多次暴露于自体病毒会增加HIV特异性免疫力并降低HIV病毒血症。
机译:延迟抗逆转录病毒治疗的HIV 1型感染可检测抗药性病毒血症患者的治疗转换不会对免疫参数产生深远影响:AIDS临床试验小组研究A5115
机译:延迟抗逆转录病毒治疗的HIV 1型感染可检测抗药性病毒血症患者的治疗转换不会对免疫参数产生深远影响:AIDS临床试验小组研究A5115
机译:HIV 1型感染患者常规获得抗逆转录病毒检测的长期疗效:耐药性试验临床疗效的结果